Johnson & Johnson announced a $5.5 billion settlement to resolve about 76,000 lawsuits alleging its talc-based baby powder caused ovarian cancer. The settlement covers federal and state claims but requires approval from 95% of claimants to finalize. J&J denies wrongdoing and sees the deal as a way to efficiently end litigation after years of mixed trial outcomes. Payments are expected to start in 2027, with total costs possibly rising above $7 billion depending on participation. The deal excludes future claims, accelerating payouts to current plaintiffs within 18 months.
The FDA has granted Priority Review to Johnson & Johnson's subcutaneous amivantamab for treating adults with recurrent or metastatic head and neck squamous cell carcinoma after progression on chemotherapy and immunotherapy. This drug uniquely targets...
In 2026, the ProShares Dividend Aristocrat ETF (NOBL) has outperformed the S&P 500 ETF (SPY), delivering a 12.9% return compared to SPY's 7.88%. Dividend Aristocrats, known for consistent dividend growth, averaged a 4.10% increase this year, with not...
Investors are rotating out of AI infrastructure stocks such as Micron and Western Digital, which surged earlier this year due to memory shortages but have recently declined. CNBC's Jim Cramer highlights a shift toward companies with broader growth dr...
Johnson & Johnson has agreed to a $5.5 billion settlement to resolve about 76,000 lawsuits alleging its talc products caused ovarian cancer. The settlement aims to conclude a decade-long legal battle and requires participation from plaintiff firms re...
Johnson & Johnson has reached a historic $5.5 billion settlement to resolve claims from about 70,000 women and families alleging its talc products, including Johnson's Baby Powder, contained asbestos and caused cancers such as ovarian cancer and meso...
